Inactive Instrument

Analyst Reco. Rubius Therapeutics

Equities

Guggenheim Downgrades Rubius Therapeutics to Neutral From Buy	22-09-13	MT
Morgan Stanley Cuts Price Target on Rubius Therapeutics to $1.50 From $2, Maintains Equalweight Rating	22-09-09	MT
SVB Leerink Adjusts Rubius Therapeutics' Price Target to $3 From $5, Keeps Market Perform Rating	22-04-11	MT
Morgan Stanley Adjusts Price Target on Rubius Therapeutics to $4 From $15, Keeps Equalweight Rating	22-04-11	MT
Guggenheim Adjusts Rubius Therapeutics' Price Target to $5 From $25, Keeps Buy Rating	22-04-11	MT
HC Wainwright Adjusts Rubius Therapeutics' Price Target to $15 From $40, Keeps Buy Rating	22-04-11	MT
SVB Leerink Adjusts Rubius Therapeutics Price Target to $5 From $14, Maintains Market Perform Rating	22-02-25	MT
Guggenheim Adjusts Rubius Therapeutics PT to $25 From $32, Maintains Buy Rating	22-01-03	MT
SVB Leerink Adjusts Rubius Therapeutics' Price Target to $14 from $20, Keeps Market Perform Rating	21-11-09	MT
RUBIUS THERAPEUTICS : Morgan Stanley Adjusts Rubius Therapeutics' Price Target to $22 from $25, Keeps Equalweight Rating	21-10-19	MT
RUBIUS THERAPEUTICS : Morgan Stanley Adjusts Rubius Therapeutics' Price Target to $25 from $24, Keeps Equalweight Rating	21-05-18	MT
RUBIUS THERAPEUTICS : Morgan Stanley Adjusts Rubius Therapeutics PT to $10 From $5, Maintains Equal Weight Rating	21-01-19	MT
RUBIUS THERAPEUTICS : Morgan Stanley Adjusts Rubius Therapeutics PT to $5 From $4, Maintains Equal Weight Rating	20-11-11	MT

No results for this search